Best Practices for Postmarket Drug Safety Surveillance: FDA Seeks Comments
snippet
The US Food and Drug Administration (FDA) on Wednesday released for public comment a draft version of best practices in drug and biologic postmarket safety surveillance.
Source
RAPS.org